Latest From 23andMe Inc.
Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
GSK has more than doubled its oncology pipeline since July 2018, and the company's CEO thinks smaller deals and a new site combining R&D and manufacturing will enable its progress to continue.
San Diego, CA-based software-as-a-service company Seqster developed a technology that integrates data from electronic health records, genomics and wearables into one platform. Seqster's CEO Ardy Arianpour believes he has solved a major interoperability problem and hopes to attract providers, payers and pharma companies as clients.
A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
- Laboratory Testing Services
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- 23andMe Inc.
- Senior Management
Anne Wojcicki, CEO
Dean Schorno, CFO & Head, Operations
Richard Scheller, PhD, CSO & Head, Therapeutics
Joyce Tung, PhD, VP, Research
Steve Lemon, VP, Product & Engineering
Kathy Hibbs, JD, Chief Legal & Regulatory Officer
Emily Drabant Conley, PhD, VP, BD
Robert Gentleman, PhD, VP, Computational Biology
Jonathan Ward, VP, Consumer Marketing & Acquisition
Tracy Keim, MS, VP, Consumer Marketing & Brand
- Contact Info
Phone: (650) 938-6300
899 West Evelyn Avenue
Mountain View, CA 94041
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.